Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

478 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting APOC3 in the familial chylomicronemia syndrome.
Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Graham MJ, Crooke RM, Witztum JL. Gaudet D, et al. Among authors: witztum jl. N Engl J Med. 2014 Dec 4;371(23):2200-6. doi: 10.1056/NEJMoa1400284. N Engl J Med. 2014. PMID: 25470695 Free article.
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.
Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB. Tsimikas S, et al. Among authors: witztum jl. N Engl J Med. 2005 Jul 7;353(1):46-57. doi: 10.1056/NEJMoa043175. N Engl J Med. 2005. PMID: 16000355 Free article.
Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E, Graham MJ, Mullick AE, Miller ER, Crooke RM, Pitas RE, Witztum JL, Tsimikas S. Merki E, et al. Among authors: witztum jl. Circulation. 2008 Aug 12;118(7):743-53. doi: 10.1161/CIRCULATIONAHA.108.786822. Epub 2008 Jul 28. Circulation. 2008. PMID: 18663084
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, Geary RS, Hughes SG, Viney NJ, Graham MJ, Crooke RM, Witztum JL, Brunzell JD, Kastelein JJ. Gaudet D, et al. Among authors: witztum jl. N Engl J Med. 2015 Jul 30;373(5):438-47. doi: 10.1056/NEJMoa1400283. N Engl J Med. 2015. PMID: 26222559 Free article. Clinical Trial.
ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.
Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD. Gordts PL, et al. Among authors: witztum jl. J Clin Invest. 2016 Aug 1;126(8):2855-66. doi: 10.1172/JCI86610. Epub 2016 Jul 11. J Clin Invest. 2016. PMID: 27400128 Free PMC article.
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S. Viney NJ, et al. Among authors: witztum jl. Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21. Lancet. 2016. PMID: 27665230 Clinical Trial.
478 results